A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2004
11/04/2004	US20040219123 recrystallization-resistant; also comprising a glycolic or hydroglycolic dispersed hydrophilic phase, a lipophilic continuous phase and an emulsifier having an HLB ranging from 2 to 7; preventing/treating the chronological or actinic skin aging and atrophy of the skin or mucous membranes
11/04/2004	US20040219114 Cream for treatment of skin injured by the sun
11/04/2004	US20040219102 Compositions for drug delivery
11/04/2004	US20040219096 Enhancing interferon gamma production using interleukin 27; treating immune and proliferative disorders
11/04/2004	CA2523157A1 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression ofthrombin receptors
11/04/2004	CA2522960A1 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor
11/04/2004	CA2522667A1 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
11/04/2004	CA2522662A1 Compositions for delivery of drug combinations
11/04/2004	CA2521531A1 Pharmaceutical composition comprising edible acids or the acid salts and its use
11/04/2004	CA2520360A1 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
11/04/2004	CA2519552A1 Extruded particles containing adverse agents such as opioid antagonists to decrease drug abuse potential
11/04/2004	CA2497410A1 Antibacterial pyrazole carboxylic acid hydrazides
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1473294A2 Substituted 1,3-oxathiolanes with antiviral properties
11/03/2004	EP1473043A1 Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
11/03/2004	EP1473041A2 Anti-allergic pharmaceutical composition
11/03/2004	EP1473040A1 Use of human parathyroid hormone
11/03/2004	EP1473034A1 Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility
11/03/2004	EP1473032A1 Use of taurine, homotaurine and/or methionine for inducing analgesia or anesthesia
11/03/2004	EP1473003A2 Drug delivery device
11/03/2004	EP1472544A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/03/2004	EP1472543A2 Methods and compositions involving the hsp 90 activator aha1
11/03/2004	EP1472540A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
11/03/2004	EP1472515A2 MINRs AS MODIFIERS FO INSULIN RECEPTOR SIGNALING AND METHODS OF USE
11/03/2004	EP1472377A2 Genetic polymorphisms in the preprotachykinin gene
11/03/2004	EP1472376A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
11/03/2004	EP1472375A1 Gene products differentially expressed in cancerous breast cells and their methods of use
11/03/2004	EP1472364A2 Truncated aggrecanase molecules
11/03/2004	EP1472287A1 Rhamnose binding protein
11/03/2004	EP1472279A1 A method for inhibiting "melanoma inhibitory activity" mia
11/03/2004	EP1472278A2 Macrocyclic peptides active against the hepatitis c virus
11/03/2004	EP1472273A2 Compositions and methods for the treatement of immune related diseases
11/03/2004	EP1472272A1 Crystalline complexes of fluticasone 2-furoate
11/03/2004	EP1472255A1 Aza-arylpiperazines
11/03/2004	EP1472251A1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
11/03/2004	EP1472250A1 Anticholinergic agents, method for producing the same and use thereof as medicaments
11/03/2004	EP1472234A1 Quinazolinone derivatives and their use as cb agonists
11/03/2004	EP1472233A1 Pyrimidine compounds
11/03/2004	EP1472225A2 2-piperazine-pyridines useful for treating pain
11/03/2004	EP1472216A2 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
11/03/2004	EP1472214A2 Compounds for inhibiting insulin secretion and methods related thereto
11/03/2004	EP1471974A1 Tumor necrosis factor combined with interferon in demyelinating diseases
11/03/2004	EP1471931A2 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
11/03/2004	EP1471927A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
11/03/2004	EP1471919A1 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
11/03/2004	EP1471917A1 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
11/03/2004	EP1471916A2 Treatment of rheumatoid arthritis using imatinie
11/03/2004	EP1471913A2 Treatment of sleep disorders using sleep target modulators
11/03/2004	EP1471912A1 Method of promoting neuronal growth
11/03/2004	EP1471909A1 Pharmaceutical composition and method for treating disorders of the central nervous system
11/03/2004	EP1471907A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases
11/03/2004	EP1471906A1 Stimulation of cpt-1 as a means to reduce weight
11/03/2004	EP1471905A1 Use of cholinesterase antagonists to treat insulin resistance
11/03/2004	EP1471900A1 Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
11/03/2004	EP1471899A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
11/03/2004	EP1471898A1 Lutein/zeaxanthin for glare protection
11/03/2004	EP1471897A2 Use of phosphodiesterase antagonists to treat insulin resistance
11/03/2004	EP1471895A1 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
11/03/2004	EP1471887A2 Nanoparticulate compositions having lysozyme as a surface stabilizer
11/03/2004	EP1471879A1 Topical glycopyrrolate product
11/03/2004	EP1471874A1 Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
11/03/2004	EP1471872A2 Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
11/03/2004	EP1471871A2 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
11/03/2004	EP1471870A2 Use of lipid conjugates in the treatment of disease
11/03/2004	EP1471849A2 Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs
11/03/2004	EP1471818A2 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/03/2004	EP1339716B1 lactam-substituted pyrazolopyridine derivatives
11/03/2004	EP1337271B1 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
11/03/2004	EP1313732B1 Oxindole derivatives
11/03/2004	EP1286957B1 Diphenylmethane derivatives
11/03/2004	EP1278547B1 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
11/03/2004	EP1267842B1 Method for producing a controlled-release tablet using a pore forming agent in the coating
11/03/2004	EP1235814B1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
11/03/2004	EP1207907B1 Compositions for treating viral infections, and methods therefor
11/03/2004	EP1207884B1 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
11/03/2004	EP1094831A4 Compositions and methods for in vitro fertilization
11/03/2004	EP1003554B1 Proton pump inhibitor in therapeutic combination with antibacterial substances
11/03/2004	EP0788305B1 Composition for inactivating irritants in fluids
11/03/2004	EP0786994B1 Use of chloride channel blockers for reducing intraocular pressure
11/03/2004	EP0722324B1 Pharmaceutical composition for immunoenhancement therapy
11/03/2004	CN1543692A Apparatus for a quick release safety connector assembly
11/03/2004	CN1543464A Novel imidazopyridine compounds with therapeutic effect
11/03/2004	CN1543451A Receptor modulators activated by peroxizonal proliferators (ppar)
11/03/2004	CN1543362A Medical products comprising a haemocompatible coating, production and use thereof
11/03/2004	CN1543358A Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
11/03/2004	CN1543356A Anti-tumor agent
11/03/2004	CN1543352A Method and material for treating immune diseases
11/03/2004	CN1543351A Method for enhancing the effectiveness of cancer therapies
11/03/2004	CN1543349A Enhanced drug delivery in transdermal systems
11/03/2004	CN1543348A Hypotensive lipid and timolol compositions and methods of using same
11/03/2004	CN1543347A Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
11/03/2004	CN1543345A Methods for selective immunomodulation using pimecrolimus
11/03/2004	CN1543343A Preparation and diabetic use of gibberellins
11/03/2004	CN1543342A Controlled heat induced rapid delivery of pharmaceuticals from skin depot
11/03/2004	CN1542001A Small molecule inhibitors of rotamase enzyme activity
11/03/2004	CN1541711A Regulation of immune responses by manipulation of intermediary metabolite levels
11/03/2004	CN1173736C Use of interleukin-18 inhibitors in inhibiting tumor metastasis
11/03/2004	CN1173710C Treatment of congestive heart failure by pretreated autologous blood
11/03/2004	CN1173705C Use of ª‰-2-hydroxymethyl-5-(5-fluctyosine-1-yl)-1,3-oxathialane in preparation of medicine and composition containing same
11/03/2004	CN1173700C Compositions and methods for amelioration of human female sexual dysfunction

1 ... 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 ... 1151